The novel Firehawk DES platform: enable safety and efficacy by Target Eluting technology

With an unrestricted educational grant from MICROPORT MEDICAL (SHANGHAI)

Chairpersons: M.B. Leon, B. Xu

Learning Objectives

  • To understand the novel technology on an abluminal groove-filled biodegradable polymer DES
  • To learn about the up-to-date clinical data on Firehawk stent
  • To understand the mechanisms of potential benefits of this novel platform

Presentations available when logged in:

  • Introduction and objectives
  • Update on the randomised TARGET I trial: 9-month angiographic, 2-year clinical, and 3-year OCT follow-up results
  • Firehawk in complex patients and lesions: 2-year follow-up of TARGET II and 3-year follow-up of long stent registry
  • Take-home message